Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 9/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.43 |
| ▸ | GRB2 | P62993 | 1/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.42 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211613 | 0.94 | OPRM1 (0.52) | BDKRB2OPRM1OPRD1CAPN1GRB2 | |
| SCHEMBL30321102 | 0.90 | BDKRB2 (0.49) | BDKRB2OPRM1OPRD1CAPN1GRB2 | |
| SCHEMBL30321103 | 0.90 | BDKRB2 (0.49) | BDKRB2OPRM1OPRD1CAPN1GRB2 | |
| SCHEMBL30211692 | 0.87 | BDKRB2 (0.43) | BDKRB2OPRM1OPRD1CAPN1NMUR2 | |
| SCHEMBL30211654 | 0.87 | OPRM1 (0.46) | BDKRB2OPRM1OPRD1CAPN1GRB2 | |
| SCHEMBL30918517 | 0.84 | OPRM1 (0.49) | BDKRB2OPRM1OPRD1CAPN1GRB2 | |
| SCHEMBL30918489 | 0.84 | OPRM1 (0.49) | BDKRB2OPRM1OPRD1CAPN1GRB2 | |
| SCHEMBL30010846 | 0.84 | NMUR2 (0.54) | BDKRB2CAPN1NMUR2NMUR1 | |
| SCHEMBL29397180 | 0.81 | OPRM1 (0.51) | BDKRB2OPRM1OPRD1CAPN1GRB2 | |
| SCHEMBL29776901 | 0.80 | GRB2 (0.53) | BDKRB2OPRM1OPRD1CAPN1GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285583-A1 | LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON, GLP-1, AND GIP TRIGONAL AGONIST | HANMI PHARM. CO., LTD. (KR) | 2023-09-14 | — | — | US | claimed |
| EP-4154870-A1 | LIQUID PREPARATION OF LONG-ACTING CONJUGATE OF GLUCAGON/GLP-1/GIP TRIGONAL AGONIST | Hanmi Pharm. Co., Ltd. (KR) | 2023-03-29 | — | — | EP | claimed |
| CN-115811970-A | Liquid formulations of long-acting conjugates of glucagon, GLP-1 and GIP triple agonists | 韩美药品株式会社 | 2023-03-17 | — | — | CN | claimed |
| US-20230285583-A1 | LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON, GLP-1, AND GIP TRIGONAL AGONIST | HANMI PHARM. CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| EP-4154870-A1 | LIQUID PREPARATION OF LONG-ACTING CONJUGATE OF GLUCAGON/GLP-1/GIP TRIGONAL AGONIST | Hanmi Pharm. Co., Ltd. (KR) | 2023-03-29 | — | — | EP | disclosed |
| CN-115811970-A | Liquid formulations of long-acting conjugates of glucagon, GLP-1 and GIP triple agonists | 韩美药品株式会社 | 2023-03-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285583-A1 | LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON, GLP-1, AND GIP TRIGONAL AGONIST | GLP1R, GIPR, GCG | BDKRB2 1142/4885OPRM1 1902/4885OPRD1 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.